Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry
Significantly Elevates Lifecore's Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance
CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ('Lifecore'), a fully integrated contract development and manufacturing organization ('CDMO'), today announced that it has appointed Thomas (Tom) Salus as chief legal and administration officer and corporate secretary. A business-focused, hands-on executive, Mr. Salus has more than 30 years of broad-based legal and management experience gained from tenures with major law firms and multi-billion-dollar corporations. He possesses a proven track record of success across a range of key legal and operational areas including corporate governance, Securities and Exchange Commission (SEC) reporting and compliance, complex domestic and international business transactions, financings, and corporate compliance. At Lifecore, Mr. Salus will be responsible for overseeing all legal activities and human resources, while playing a key role in strategy development and corporate development activities focused on strategic alliances and partnerships.
Mr. Salus spent the past 11 years with Viatris Inc., a multi-billion-dollar, Nasdaq-listed international pharmaceutical company, most recently serving as general counsel - corporate, securities & transactions and assistant secretary. In this role, among other legal leadership responsibilities, Mr. Salus served as lead attorney for Viatris' global business development and other complex transactions, and for the company's SEC and Nasdaq reporting and compliance activities. He also collaborated extensively with the company's corporate secretary with respect to Viatris' corporate governance activities. During his career, he also held key legal leadership positions with VWR International (now part of Avantor, Inc.), a multi-billion-dollar international distributor of laboratory equipment, chemicals and supplies for the life science industry, and PPL Corporation, a Fortune 500 diversified energy company. Prior to joining industry, Mr. Salus was an attorney at several major law firms, including Faegre Drinker Biddle & Reath LLP.
'Tom's appointment is the latest action by Lifecore to strengthen our organization by adding top-tier talent to our leadership team. Having in-house counsel will be particularly valuable to drive corporate governance and SEC/Nasdaq reporting and compliance as we continue to streamline the processes that impact performance in these areas,' said Paul Josephs, president and chief executive officer of Lifecore. 'We are excited to bring Tom on board and benefit from his wealth of experience, particularly his deep expertise across several key segments within the life sciences industry. Beyond his legal expertise, Tom is well known for his strategic prowess, and he will play a key role in the continued development and implementation of our growth strategies.'
'Over the past several months, Lifecore has made impressive progress reshaping the company, as well as executing against our strategic growth strategy. I am thrilled to have the opportunity to join the leadership team and contribute to the continuation of this exciting work,' stated Mr. Salus. 'As the sole publicly listed, pure-play CDMO, Lifecore holds a unique place in the industry, and I am eager to apply my broad legal and management experience to drive success that maximizes this position.'
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore's website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as 'anticipate', 'estimate', 'expect', 'project', 'plan', 'intend', 'believe', 'may', 'might', 'will', 'should', 'can have', 'likely' and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our anticipated future customer opportunities and relationships are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the company's ability to successfully enact its business strategies, including with respect to installation, capacity generation and its ability to attract demand for its services, and its ability expand its relationship with its existing customers or attract new customers; the impact of inflation on the company's business and financial condition; changes in business conditions and general economic conditions both domestically and globally including rising interest rates and fluctuation in foreign currency exchange rates; the company's ability to access to sufficient capital to fund its business strategies; and other risk factors set forth from time to time in the company's SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 26, 2024 (the '2024 10-K'). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2024 10-K. Forward-looking statements represent management's current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 minutes ago
- Globe and Mail
Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?
Those who invest in shares of Tesla Inc. (NASDAQ: TSLA) know that they are signed up for one of the wildest roller coaster rides in the stock market today, not only because the stock has been historically volatile but also because the company's CEO, Elon Musk, is starting to get involved in other areas that could potentially turn his attention away from what needs to be done to secure Tesla's leadership and future. [content-module:CompanyOverview|NASDAQ:TSLA] As most are aware, Musk has resigned from his role in a special government agency called the Department of Government Efficiency (DOGE, for short). While the intentions were good regarding the type of work this agency was to accomplish, disagreements between Musk and President Trump have driven two opposing views to a volatile week in Tesla stock, leaving some shareholders to incur losses as collateral damage. Seasoned Wall Street participants would see the recent panic as an opportunity in the technology sector, especially for shareholders eyeing lower prices. For Tesla, however, this is where the charts become particularly useful. This is important, especially when viewed through an auction lens, because there is an obvious price that Tesla could reach before providing an optimal entry point. Gaming: The Future of Tesla Now that Musk can focus his energy on Tesla's development, one clear objective will be fulfilled in the coming months and quarters. The race to make the robotaxi dream a reality should return to the CEO's forefront, especially as new competition has entered the scene. Waymo, an autonomous driving platform owned by Alphabet Inc. (NASDAQ: GOOGL), has already made significant progress in this space, averaging up to 250,000 rides per week. Whether it is due to technological superiority, market share, or sheer adoption from end users, Tesla now has a lot of ground to make up in this regard. This is one positive catalyst investors can look forward to today, especially as Musk is set to come back to the ground floor at Tesla. With this in mind, investors should still command a price for the stock that prices out most (if not all) of the potential downside that could arise from this current political feud. With a robotaxi announcement expected in the coming weeks of June 2025, it is high time for investors to strategize their positioning in the stock before the information spreads out more quickly than they can react to it. For this reason, the following technical level should also be kept in mind. Where Tesla Can Be Bought Examining the one-year chart for Tesla, investors can identify a significant inefficiency. During late April 2025, the price jumped aggressively from $259 per share to $288 per share in a matter of hours, creating a pattern that some would call a buy-side imbalance, where the auction left little to no time for investors to enter and chase the upward momentum in price. On a psychological level, this means there are still bulls waiting on the sidelines for this price, making it a mental and emotional anchor for buy orders to be executed again. In fact, the $270 mark represented solid support due to this development, where impatient buyers couldn't wait to retest the lower end of the breakout and had to get in. After falling by roughly 15% in one week, the $270 area acted as a backstop for further selling, accurately fulfilling this technical and psychological setup. Therefore, those looking to buy have two choices from today's $295 per share price. One option is to make room for the price to move up toward the $310 mark again, where the opposite pattern formed. On the way down, numerous sell-side inefficiencies formed, as a fast auction didn't allow sellers to exit and cut their losses. Given the uncertainty, it wouldn't be too far from reality to expect these beaten-down bulls to revisit that price before letting go of their shares. [content-module:TradingView|NASDAQ:TSLA] So now investors can watch the reaction in Tesla's price in this range; if it continues to act as 'resistance,' then they can rest assured that the lower price area near $270 will be tested again. At this point, they will have another incentive to open new positions on the long side. Here's a good sign that supports this view: up to $20 billion of institutional buying took place over the recent quarter for Tesla stock, a period that overlaps with this inefficiency, with the stock reaching the $270 mark, indicating a footprint of institutional liquidity advantages being taken. The map is laid out, and at 60% of its 52-week high, Tesla stock offers new investors a great risk-to-reward ratio moving forward, especially with a new $500 per share price target set by Dan Ives, an analyst from Wedbush Securities as of early June 2025. In his view, Tesla promises a rally of up to 70% from its current level. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
Winnipeg Free Press
4 hours ago
- Winnipeg Free Press
S&P/TSX composite edges lower in late-morning trading, U.S. stocks mixed
TORONTO – Canada's main stock index edged lower in late-morning trading, weighed down by losses in the base metal and technology sectors, while U.S. stock markets were mixed. The S&P/TSX composite index was down 10.32 points at 26,365.48. In New York, the Dow Jones industrial average was down 11.02 points at 42,750.74. The S&P 500 index was up 1.56 points at 6,007.44, while the Nasdaq composite was down 8.57 points at 19,582.67. The Canadian dollar traded for 73.11 cents US compared with 73.08 cents US on Monday. The July crude oil contract was up 84 cents US at US$66.13 per barrel and the July natural gas contract was down eight cents US at US$3.55 per mmBTU. The August gold contract was down US$8.20 at US$3,346.70 an ounce and the July copper contract was down two cents US at US$4.91 a pound. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published June 10, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
Globe and Mail
5 hours ago
- Globe and Mail
Strategy (MSTR) Buys Another $110 Million of Bitcoin
Strategy (MSTR) continues to purchase Bitcoin (BTC) even as the price rises. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In the past week, the software company turned serial Bitcoin acquirer bought an additional 1,045 BTC for $110.2 million. The company, led by founder Michael Saylor, paid an average purchase price of $105,426 each for its latest Bitcoin accumulation. Strategy, formerly known as MicroStrategy, now owns 582,000 Bitcoin worth $62.5 billion. The company is the largest corporate owner of BTC in the world. Strategy's average purchase price for its Bitcoin holdings is $70,086 per digital token. Funding Purchases Last week's buys were funded via at-the-market sales of Strategy's preferred stock, according to a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company remains committed to its focus on aggressively acquiring Bitcoin. Strategy's stock has risen 25% this year to trade at $374.47 per share. The price of Bitcoin is currently right around $107,500, having gained 12% on the year. Is BTC a Buy? Most Wall Street firms don't offer ratings or price targets on Bitcoin, so we'll look instead at its three-month performance. As one can see in the chart below, the price of BTC has risen 34.14% in the last 12 weeks.
